Ylva Terelius

1.6k total citations
33 papers, 1.3k citations indexed

About

Ylva Terelius is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Ylva Terelius has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 12 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Ylva Terelius's work include Pharmacogenetics and Drug Metabolism (19 papers), Drug Transport and Resistance Mechanisms (10 papers) and Eicosanoids and Hypertension Pharmacology (7 papers). Ylva Terelius is often cited by papers focused on Pharmacogenetics and Drug Metabolism (19 papers), Drug Transport and Resistance Mechanisms (10 papers) and Eicosanoids and Hypertension Pharmacology (7 papers). Ylva Terelius collaborates with scholars based in Sweden, United Kingdom and Japan. Ylva Terelius's co-authors include Magnus Ingelman‐Sundberg, Jan‐Olov Persson, Moustapha Hassan, Emanuele Albano, Paolo Clot, Inger Johansson, Erik Eliasson, Anders Rane, Ümit Yaşar and Laimonas Griškevičius and has published in prestigious journals such as Blood, PLoS ONE and Analytical Biochemistry.

In The Last Decade

Ylva Terelius

33 papers receiving 1.2k citations

Peers

Countries citing papers authored by Ylva Terelius

Since Specialization

Citations

This map shows the geographic impact of Ylva Terelius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ylva Terelius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ylva Terelius more than expected).

Fields of papers citing papers by Ylva Terelius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ylva Terelius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ylva Terelius. The network helps show where Ylva Terelius may publish in the future.

Co-authorship network of co-authors of Ylva Terelius

This figure shows the co-authorship network connecting the top 25 collaborators of Ylva Terelius. A scholar is included among the top collaborators of Ylva Terelius based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ylva Terelius. Ylva Terelius is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluation of ADMET Predictor in Early Discovery Drug Metabolism and Pharmacokinetics Project Work 2021 ·Drug Metabolism and Disposition ·Anna-Karin Sohlenius-Sternbeck, Ylva Terelius	36
2	The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection 2021 ·Cells ·Natalia Landázuri, Jennifer Gorwood, Ylva Terelius, Fredrik Öberg, Koon-Chu Yaiw, Afsar Rahbar, Cecilia Söderberg‐Nauclér	1
3	Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711 2018 ·Journal of Translational Medicine ·Erik Lindström, (unknown), Ian Henderson, Ylva Terelius, Markus Jerling, Charlotte Edenius, Urszula Grabowska	37
4	Cytochrome P450 2J2, a new key enzyme in cyclophosphamide bioactivation and a potential biomarker for hematological malignancies 2015 ·The Pharmacogenomics Journal ·Ibrahim El‐Serafi, Mohammad M. Fares, Manuchehr Abedi‐Valugerdi, Parvaneh Afsharian, Ali Moshfegh, Ylva Terelius, (unknown), Moustapha Hassan	24
5	Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes 2015 ·Chemico-Biological Interactions ·Ylva Terelius, Robert A. Figler, Svetlana Marukian, Maria Sol Collado, Mark Lawson, Aaron J. Mackey, David Manka, Charles W. Qualls, Brett R. Blackman, Brian R. Wamhoff, Ajit Dash	27
6	Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation 2015 ·PLoS ONE ·Ibrahim El‐Serafi, Parvaneh Afsharian, Ali Moshfegh, Moustapha Hassan, Ylva Terelius	30
7	Gas chromatographic–mass spectrometry method for the detection of busulphan and its metabolites in plasma and urine 2012 ·Journal of Chromatography B ·Ibrahim El‐Serafi, Ylva Terelius, (unknown), Ann-Louise Hagbjörk, Zuzana Hassan, Moustapha Hassan	16
8	Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development 2012 ·Bioorganic & Medicinal Chemistry Letters ·Patrick Raboisson, Anna Breitholtz‐Emanuelsson, (unknown), Louise Edwards, William L. Heaton, Methvin Isaac, Keith R. Jarvie, Annika Kers, Alexander B. E. Minidis, Anna Nordmark, Susan Sheehan, Abdelmalik Slassi, Peter Ström, Ylva Terelius, David Wensbo, Julie M. Wilson, (unknown), Donald A. McLeod	29
9	Quantification of interactions between drug leads and serum proteins by use of “binding efficiency” 2010 ·Analytical Biochemistry ·(unknown), Lotta Vrang, Ylva Terelius, U. Helena Danielson	12
10	Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone 2009 ·Drug Metabolism and Disposition ·(unknown), R. Michael Baldwin, (unknown), Ylva Terelius, Ronny Fransson-Steen, Jessica Mwinyi, David J. Waxman, Magnus Ingelman‐Sundberg	20
11	Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression 2008 ·Drug Metabolism and Disposition ·(unknown), R. Michael Baldwin, Masahiro Hiratsuka, (unknown), (unknown), Sarah C. Sim, (unknown), (unknown), (unknown), Ronny Fransson-Steen, Ylva Terelius, Magnus Ingelman‐Sundberg	39
12	Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat 2005 ·Xenobiotica ·Hong Xie, Parvaneh Afsharian, Ylva Terelius, Rajaa A. Mirghani, Ümit Yaşar, (unknown), (unknown), Yin Hu, Anders Rane, Moustapha Hassan	15
13	Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison 2004 ·Xenobiotica ·(unknown), (unknown), (unknown), Ronny Fransson-Steen, Ylva Terelius	51
14	Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation 2003 ·The Pharmacogenomics Journal ·(unknown), Ümit Yaşar, (unknown), Laimonas Griškevičius, Ylva Terelius, Moustapha Hassan, Anders Rane	180
15	Ethanol-inducible cytochrome P4502E1: Genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease 1993 ·Alcohol ·Magnus Ingelman‐Sundberg, Inger Johansson, (unknown), Ylva Terelius, Erik Eliasson, Paolo Clot, Emanuele Albano	199
16	Exposure to various benzene derivatives differently induces cytochromes P450 2B1 and P450 2E1 in rat liver 1993 ·Archives of Toxicology ·Ivan Gut, Ylva Terelius, E Frantík, Igor Linhart, Pavel Souček, (unknown), (unknown)	40
17	Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols 1991 ·Biochemical Pharmacology ·Emanuele Albano, Aldo Tomasi, Jan‐Olov Persson, Ylva Terelius, Lucia Goria-Gatti, Magnus Ingelman‐Sundberg, Umberto Dianzani	115
18	Hydroxylation of salicylate by microsomal fractions and cytochrome P-450. Lack of production of 2,3-dihydroxybenzoate unless hydroxyl radical formation is permitted 1991 ·Biochemical Journal ·Magnus Ingelman‐Sundberg, Harsimran Kaur, Ylva Terelius, Jan‐Olov Persson, Barry Halliwell	112
19	Cytochrome P-450-dependent formation of reactive oxygen radicals: isozyme-specific inhibition of P-450-mediated reduction of oxygen and carbon tetrachloride 1990 ·Xenobiotica ·Jan‐Olov Persson, Ylva Terelius, Magnus Ingelman‐Sundberg	73
20	Cytochrome P-450-dependent oxidase activity and hydroxyl radical production in micellar and membranous types of reconstituted systems 1988 ·Biochemical Pharmacology ·Ylva Terelius, Magnus Ingelman‐Sundberg	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact